Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Roberta Champouillon

Nurse Practitioner, Family Albuquerque, NM Nurse Practitioner

NPI 1134850779 CMS profile 11310860

5310 Homestead Rd Ne Bldg 4, Albuquerque, NM 87110

Open in the dashboard

General payments

$6,003

195 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Roberta Champouillon of Albuquerque, NM is reported in the CMS Open Payments database as having received $6,003 across 195 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,340 49
2024 General $1,592 56
2023 General $1,768 56
2022 General $1,302 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Roberta Champouillon
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Roberta Champouillon were reported at $1,340. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Roberta Champouillon Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $0 $124 $35–$379 $132
2022 $1,302 $141 $44–$430 $149
2023 $1,768 $154 $49–$476 $160
2024 $1,592 $165 $51–$504 $164
2025 $1,340 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AstraZeneca Pharmaceuticals LP $955 21 payments
  2. AbbVie, Inc. $876 53 payments
  3. ITI, Inc. $859 15 payments
  4. Novo Nordisk Inc $472 19 payments
  5. Alkermes, Inc. $423 4 payments
  6. Teva Pharmaceuticals USA, Inc. $376 5 payments
  7. Lilly USA, LLC $375 17 payments
  8. Idorsia Pharmaceuticals US Inc $332 8 payments
  9. Otsuka America Pharmaceutical, Inc. $233 7 payments
  10. Exact Sciences Corporation $223 10 payments
  11. Other $877 36 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $5,904 191 payments
  2. Education $98 4 payments
Products named General payments · program years 2022–2025
  1. CAPLYTA $717 13 payments
  2. FARXIGA $609 12 payments
  3. QULIPTA $479 38 payments
  4. MOUNJARO $357 16 payments
  5. QUVIVIQ $332 8 payments
  6. LYBALVI Cns $325 3 payments
  7. LYBALVI Cns $325 3 payments
  8. LYBALVI Cns $325 3 payments
  9. LYBALVI Cns $325 3 payments
  10. VRAYLAR $313 8 payments
  11. Other $3,654 130 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

710

Median for Nurse Practitioner: 389

Drug cost

$10,188

Median for Nurse Practitioner: $21,885

Branded share of claims

16.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Progesterone Progesterone, Micronized Brand 73 $2,486
Levothyroxine Sodium Generic 72 $1,096
Gabapentin Generic 58 $659
Tramadol Hcl Generic 28 $592
Albuterol Sulfate Hfa Albuterol Sulfate Brand 17 $420
Amitriptyline Hcl Generic 12 $379
Fluticasone Propionate Generic 16 $364
Atorvastatin Calcium Generic 23 $320
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 11 $313
Propranolol Hcl Generic 13 $299

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
  • ITI, Inc. $357
$357 — —
QULIPTA
  • AbbVie, Inc. $174
$174 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $141
$141 — —
MOUNJARO
  • Lilly USA, LLC $139
$139 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $122
$122 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

195 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in New Mexico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record